AQP4 and optic neuritis: The present study demonstrates that initiation of the biologic agents satralizumab in patients with NMOSD demonstrates the possibility of reducing the dose of or discontinuing steroids after initiation, and was highly effective in preventing relapse of AQP4-Ab positive optic neuritis.